Company Description
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.
The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma.
It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe.
Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
| Country | United States |
| Founded | 1988 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 76 |
| CEO | Gerard J. Michel MBA, MS |
Contact Details
Address: 566 Queensbury Avenue Queensbury, New York 12804 United States | |
| Phone | (518) 743-8892 |
| Website | delcath.com |
Stock Details
| Ticker Symbol | DCTH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000872912 |
| CUSIP Number | 24661P807 |
| ISIN Number | US24661P8077 |
| Employer ID | 06-1245881 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Gerard J. Michel MBA, MS | Chief Executive Officer and Director |
| Dr. Johnny John M.D. | Senior Vice President of Clinical Operations and Medical Affairs |
| Sandra Pennell | Senior Vice President of Finance and Principal Financial and Accounting Officer |
| Dr. Martha S. Rook Ph.D. | Chief Operating Officer |
| David Hoffman | General Counsel, Corporate Secretary and Chief Compliance Officer |
| Dr. Vojislav Vukovic M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 26, 2024 | 8-K | Current Report |
| Apr 12, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 12, 2024 | ARS | Filing |
| Apr 12, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 26, 2024 | D | Notice of Exempt Offering of Securities |
| Mar 26, 2024 | 10-K | Annual Report |
| Mar 26, 2024 | 8-K | Current Report |
| Mar 25, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 19, 2024 | 8-K | Current Report |